Market Overview

UPDATE: Sterne Agee Reiterates Buy Rating, Raises PT on MedAssets

Related MDAS
Mercy Medical Center Selects MedAssets for Supply Chain Management and Performance Improvement Solutions
Benzinga's Top Downgrades

In a report published Monday, Sterne Agee Group reiterated its Buy rating on MedAssets (NASDAQ: MDAS), and raised its price target from $22.00 to $24.00.

Sterne Agee noted, “At the start of 2012, MDAS was trading around 7.5x the consensus FY2 EBITDA estimate. By year-end, that multiple had risen to 9x. MDAS' FY2 P/E multiple also increased from 9x to 14x. These metrics underscore the success of the company's turnaround efforts. We foresee the stock reaching the mid $20s over the next 12 months. Our $24 price target is based on 9.5x our CY14 EBITDA estimate of $240 million.”

MedAssets closed on Friday at $18.60.

Latest Ratings for MDAS

Jan 2016SunTrust Robinson HumphreyTerminatesNeutral
Nov 2015JP MorganAssumesNeutral
Nov 2015SunTrust Robinson HumphreyDowngradesBuyNeutral

View More Analyst Ratings for MDAS
View the Latest Analyst Ratings

Posted-In: Sterne Agee GroupAnalyst Color Price Target Analyst Ratings


Related Articles (MDAS)

View Comments and Join the Discussion!

Partner Center